# A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Source: https://onco.cc/trials/nct07069712/  
OnCo record `nct07069712` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sonesitatug vedotin, Rilvegostomig, Trastuzumab, Trastuzumab deruxtecan, Capecitabine and Fluorouracil (5-FU) in oesophageal cancer, run by AstraZeneca, now recruiting.

## Summary

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma is a phase 2 interventional study registered as NCT07069712 by AstraZeneca, with 100 participants planned, started 2025-07-17 and due to reach its primary completion in 2027-11-03. Interventions recorded: Sonesitatug Vedotin, Rilvegostomig, Trastuzumab Deruxtecan (T-DXd), Capecitabine, 5-Fluorouracil (5-FU) and FLOT Chemotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07069712
- Phase: 2
- Setting: A Master Protocol of an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)
- Sponsor: AstraZeneca
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07069712: https://clinicaltrials.gov/study/NCT07069712

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Rilvegostomig](https://onco.cc/drugs/rilvegostomig/), [Sonesitatug vedotin](https://onco.cc/drugs/cmg901/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Parexel](https://onco.cc/companies/parexel/)

---
JSON: https://onco.cc/api/v1/entities/nct07069712.json